Market closedNon-fractional
23andMe/ME
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About 23andMe
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Ticker
ME
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Providers and Services
Headquarters
South San Francisco, United States
Employees
571
Website
www.23andme.com
23andMe Metrics
BasicAdvanced
$227M
Market cap
-
P/E ratio
-$1.40
EPS
1.28
Beta
-
Dividend rate
Price and volume
Market cap
$227M
Beta
1.28
Financial strength
Current ratio
2.005
Quick ratio
1.726
Long term debt to equity
35.988
Total debt to equity
40.587
Management effectiveness
Return on assets (TTM)
-30.03%
Return on equity (TTM)
-147.75%
Valuation
Price to revenue (TTM)
0.971
Price to book
1.17
Price to tangible book (TTM)
1.63
Price to free cash flow (TTM)
-1.226
Growth
Revenue change (TTM)
-26.66%
Earnings per share change (TTM)
102.92%
3-year revenue growth (CAGR)
-3.44%
3-year earnings per share growth (CAGR)
-8.73%
What the Analysts think about 23andMe
Analyst Ratings
Majority rating from 2 analysts.
23andMe Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q4 24
QoQ growth
Revenue
$64M
43.18%
Net income
-$209M
-24.87%
Profit margin
-326.25%
-47.52%
23andMe Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 24
Q2 24
Q3 24
Q4 24
Q1 25
Actual
-$0.23
-$0.16
-$0.16
-$0.11
-
Expected
-$0.15
-$0.14
-$0.14
-$0.15
-$0.22
Surprise
53.85%
13.88%
14.29%
-26.67%
-
23andMe News
AllArticlesVideos
23andMe to Report Q1 FY2025 Financial Results
GlobeNewsWire·1 day ago
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research
GlobeNewsWire·2 days ago
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for 23andMe stock?
23andMe (ME) has a market cap of $227M as of July 27, 2024.
What is the P/E ratio for 23andMe stock?
The price to earnings (P/E) ratio for 23andMe (ME) stock is 0 as of July 27, 2024.
Does 23andMe stock pay dividends?
No, 23andMe (ME) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next 23andMe dividend payment date?
23andMe (ME) stock does not pay dividends to its shareholders.
What is the beta indicator for 23andMe?
23andMe (ME) has a beta rating of 1.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell 23andMe stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.